Phase II trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.

e15076 Background: Sunitinib is a standard front-line treatment for metastatic renal cell carcinoma (mRCC) patients (pts), but is not proven to be beneficial in pts with poor-risk clinical features...